ClassID:

109054

C12N15/1137 - CPC Classification

Classification description:

Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides against enzymes

Recent Application in this class:
#1
20260152751
2026-06-04

INTERFERING RNA FOR INHIBITING JAK1 GENE EXPRESSION AND USE THEREOF

#2
20260152750
2026-06-04

RNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF

#3
20260151417
2026-06-04

Nucleic acid regulation of c9orf72

#4
20260146252
2026-05-28

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#5
20260146251
2026-05-28

DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE

#6
20260146250
2026-05-28

MICROPARTICLE, PREVENTIVE DRUG OR THERAPEUTIC DRUG FOR ERECTILE DYSFUNCTION, AND METHOD FOR IMPROVING ERECTILE DYSFUNCTION

#7
20260146249
2026-05-28

ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP

#8
20260139328
2026-05-21

NOVEL MICROBIAL GENOTOXINS

#9
20260139256
2026-05-21

Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors

#10
20260139255
2026-05-21

RNAi Agent Targeting PCSK9 and Use Thereof

#11
20260139254
2026-05-21

INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF

#12
20260137807
2026-05-21

COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL

#13
20260132406
2026-05-14

RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use

#14
20260131024
2026-05-14

GENE THERAPY FOR PRADER WILLI SYNDROME

#15
20260130937
2026-05-14

COMPOSITION AND METHODS TO REDUCE INFLAMMATION AND PROMOTE REJUVENATION

#16
20260130910
2026-05-14

METHODS OF TREATING CANCERS

#17
20260125685
2026-05-07

THERAPEUTIC AGENT FOR TREATING HIF-1alpha-MEDIATED DISEASES BY INHIBITING AREL1 AND RESTORING PHD2 ACTIVITY

#18
20260125684
2026-05-07

NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE

#19
20260125683
2026-05-07

TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE

#20
20260125682
2026-05-07

CHEMICAL MODIFICATIONS OF SMALL INTERFERING RNA WITH MINIMAL FLUORINE CONTENT

#21
20260124249
2026-05-07

USE OF TNKS INHIBITORS FOR REGENERATION OF CARTILAGE

#22
20260117233
2026-04-30

PLATELETS TRANSFECTED WITH SIRNA AND THE THERAPEUTICS USES THEREOF

#23
20260117232
2026-04-30

ANTISENSE OLIGONUCLEOTIDE, COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF FOR EXON SKIPPING

#24
20260115243
2026-04-30

ANTIBACTERIAL PHAGE, THERAPEUTIC COMPOSITION, BACTERICIDAL AGENT, FOOD, BACTERIA IDENTIFICATION KIT, THERAPEUTIC COMPOSITION MANUFACTURING METHOD, BACTERIA ELIMINATION METHOD, BACTERIA IDENTIFICATION METHOD, AND ANIMAL THERAPEUTIC METHOD

#25
20260115223
2026-04-30

METHODS OF TREATING MYELODYSPLASTIC SYNDROME

#26
20260115222
2026-04-30

Compounds and Methods for Reducing ATXN3 Expression

#27
20260109988
2026-04-23

COMPOSITIONS AND METHODS TO MODULATE TUMOR MICROENVIRONMENT ASSOCIATED LONG NONCODING RNAS

#28
20260109985
2026-04-23

THERAPY BY TRANS-SPLICING OF OPA1 PRE-MESSENGER RNAS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OPA1 GENE MUTATIONS

#29
20260108631
2026-04-23

Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Reduction

#30
20260103714
2026-04-16

ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE

#31
20260103713
2026-04-16

MICROPARTICLE, AGENT FOR ACTIVATING NK CELL, METHOD FOR CULTURING NK CELL, METHOD FOR PRODUCING ACTIVATED NK CELL, AND METHOD FOR ACTIVATING NK CELL

#32
20260103712
2026-04-16

ANTI-FIBROTIC MICRORNA COMPOSITION

#33
20260102500
2026-04-16

PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING

#34
20260098268
2026-04-09

COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S DISEASE AND OTHER BRAIN DISEASES

#35
20260097102
2026-04-09

Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors

#36
20260092280
2026-04-02

NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE

#37
20260085321
2026-03-26

IRON METABOLISM TARGETS FOR OBESITY

#38
20260085320
2026-03-26

GALNAC MONOMER COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF AND USE THEREOF IN LIVER-TARGETED DELIVERY OF SMALL NUCLEIC ACID DRUGS

#39
20260085319
2026-03-26

COMPOSITIONS FOR USE IN THE TREATMENT OF CHD2 HAPLOINSUFFICIENCY

#40
20260078398
2026-03-19

PLANTS GENETICALLY ENGINEERED FOR INCREASED WATER USE EFFICIENCY AND CARBON INTAKE AND METHODS FOR MAKING AND USING THEM

#41
20260078379
2026-03-19

Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms

#42
20260078378
2026-03-19

Treatment Of Sepsis With PCSK9 And LDLR Modulators

#43
20260069710
2026-03-12

LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF

#44
20260069541
2026-03-12

COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS

#45
20260062706
2026-03-05

Treatment Of Pan-Cancer Phenotype With Regulator of Telomere Elongation Helicase 1 (RTEL1) Inhibitors

#46
20260062705
2026-03-05

TREATMENT FOR OVARIAN CANCER WITH OLIGONUCLEOTIDES TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA

#47
20260055414
2026-02-26

COMPOSITIONS AND METHODS FOR INHIBITING XDH EXPRESSION

#48
20260049320
2026-02-19

RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING EXPRESSION OF DYSTROPHIA MYOTONICA PROTEIN KINASE AND/OR INTERFERING WITH A TRINUCLEOTIDE REPEAT EXPANSION IN THE 3' UNTRANSLATED REGION OF THE DMPK GENE

#49
20260049319
2026-02-19

TREM2 BINDS TO SPECIFICALLY STRUCTURED HEPARAN SULFATE

#50
20260049318
2026-02-19

INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION

#51
20260049317
2026-02-19

GalNAc Compound Containing Triazole Structure and Oligonucleotide Conjugate Thereof

#52
20260049316
2026-02-19

ANTISENSE OLIGONUCLEOTIDE FOR INHIBITING ACSL4 GENE EXPRESSION AND ITS APPLICATIONS

#53
20260049315
2026-02-19

SOD1 DUAL EXPRESSION VECTORS AND USES THEREOF

#54
20260049120
2026-02-19

EXPRESSION OF FC-CONTAINING PROTEINS

#55
20260048120
2026-02-19

MODIFIED IMMUNE CELLS AND USES THEREOF

#56
20260043039
2026-02-12

METHODS OF ALTERING THE STARCH GRANULE PROFILE IN PLANTS

#57
20260043031
2026-02-12

COMPOSITIONS AND METHODS FOR INHIBITING ADENYLATE CYCLASE 9 (AC9)

#58
20260043030
2026-02-12

Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (LRRK2) and its use for preventing and/or treating human diseases

#59
20260042843
2026-02-12

METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS

#60
20260035702
2026-02-05

PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#61
20260035701
2026-02-05

METHODS AND COMPOSITIONS FOR TARGETING SERINE DEHYDRATASE

#62
20260035698
2026-02-05

COMPRISING EXOSOMAL MIR-664A-5P AS AN ACTIVE INGREDIENT, A DIAGNOSTIC BIOMARKER COMPOSITION FOR PARP INHIBITOR RESPONSE AND A PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT

#63
20260034213
2026-02-05

SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER

#64
20260028631
2026-01-29

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#65
20260028630
2026-01-29

HYBRID OLIGONUCLEOTIDES

#66
20260028629
2026-01-29

AGENTS FOR MODULATING EXPRESSION

#67
20260028585
2026-01-29

METHOD FOR PREPARING ENHANCED CAR-T-CELLS BASED ON INTERFERING OR KNOCKING OUT HUMAN PCSK9 GENE AND APPLICATION THEREOF

#68
20260022384
2026-01-22

ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF

#69
20260022383
2026-01-22

SUBPOPULATION-DIRECTED REMEDIATION OF DISEASE-ASSOCIATED GENE PRODUCTS

#70
20260022382
2026-01-22

Compositions and Methods for Modulating Complement Factor B Expression

#71
20260022381
2026-01-22

RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use

#72
20260022380
2026-01-22

GENETIC MODULATORS OF KRAS PROTEIN EXPRESSION AND THEIR USES

#73
20260015617
2026-01-15

DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE

#74
20260015613
2026-01-15

FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#75
20260014266
2026-01-15

COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY

#76
20260009037
2026-01-08

RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use

#77
20260009036
2026-01-08

INHIBITORS OF EXPRESSION AND/OR FUNCTION

#78
20260009035
2026-01-08

GALNAC COMPOUND CONTAINING RIBOSE RING OR ITS DERIVATIVE STRUCTURE AND OLIGONUCLEOTIDE CONJUGATE THEREOF

#79
20260002176
2026-01-01

ADENO-ASSOCIATED VIRUS GENE THERAPY PRODUCTS AND METHODS

#80
20260002163
2026-01-01

COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER

#81
20260002161
2026-01-01

OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION

#82
20260002160
2026-01-01

SIRNA TARGETING AND REGULATING PCSK9 GENE EXPRESSION AND USE THEREOF

#83
20260000689
2026-01-01

TARGETING CREB-HEPARAN SULFATE-FGF PATHWAY FOR CANCER TREATMENT

#84
20250389713
2025-12-25

OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION

#85
20250382621
2025-12-18

IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY

#86
20250382620
2025-12-18

SIRNA TARGETING RECQL1 HELICASE GENE

#87
20250382617
2025-12-18

DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS FOR RNA INTERFERENCE AND METHODS RELATING THERETO

#88
20250381285
2025-12-18

COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY

#89
20250378926
2025-12-11

METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

#90
20250376688
2025-12-11

RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use

#91
20250376685
2025-12-11

COMBINATION VECTORS AND METHODS FOR TREATING CANCER

#92
20250375388
2025-12-11

COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS

#93
20250368998
2025-12-04

NUCLEOTIDE ANALOGUES, AND PREPARATION AND APPLICATION THEREOF

#94
20250368997
2025-12-04

Compositions and Methods for GYS1 Inhibition

#95
20250367319
2025-12-04

Targeted Nanomedicine for Treating Fibrotic Lung Disorders

#96
20250367310
2025-12-04

MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY

#97
20250367152
2025-12-04

Inducing Proliferation of Cardiomyocytes and Therapeutic Uses Related Thereto

#98
20250354153
2025-11-20

SYSTEMS FOR CELL PROGRAMMING AND METHODS THEREOF

#99
20250354152
2025-11-20

PHARMACEUTICAL COMPOUND FOR PREVENTION OR TREATMENT OF LIVER FIBROSIS

#100
20250354151
2025-11-20

INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE

#101
20250352672
2025-11-20

METHOD FOR TREATMENT OF MYOTONIC DYSTROPHY COMBINING PROTEIN EXPRESSION AND RNA INTERFERENCE VECTOR DELIVERY WITH TISSUE DETARGETING

#102
20250346903
2025-11-13

USE OF CONJUGATES OF MICRORNA AND CARDIAC TARGETING PEPTIDES FOR TREATING HEART FAILURE

#103
20250346902
2025-11-13

RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF

#104
20250340886
2025-11-06

INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF

#105
20250340885
2025-11-06

COMPOSITIONS AND METHODS FOR MODULATING CONDITIONS ASSOCIATED WITH ALTERED ATP8B1 FUNCTION

#106
20250340884
2025-11-06

ANTISENSE OLIGOMERS AGAINST MONOAMINE OXIDASE B AND USE THEREOF

#107
20250340883
2025-11-06

Method For Treating Cyclophilin B Associated Diseases

#108
20250339546
2025-11-06

GLIOBLASTOMA TUMOR GROWTH INHIBITON BY SAT1 KNOCKDOWN

#109
20250333743
2025-10-30

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#110
20250333742
2025-10-30

COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

#111
20250333741
2025-10-30

Conjugated Antisense Compounds and Their Use

#112
20250333740
2025-10-30

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

#113
20250333737
2025-10-30

17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#114
20250332238
2025-10-30

INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER

#115
20250327124
2025-10-23

METHOD FOR TESTING PULMONARY HYPERTENSION, PATHOLOGICAL ANIMAL MODEL FOR PULMONARY ARTERIAL HYPERTENSION, AND PREVENTIVE OR THERAPEUTIC AGENT FOR PULMONARY HYPERTENSION

#116
20250327079
2025-10-23

METHOD FOR CARDIAC REPAIR

#117
20250320503
2025-10-16

AAV VECTORS ENCODING SOD1-TARGETING ARTIFICIAL MIRNAS (AMI-RNA)

#118
20250320502
2025-10-16

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

#119
20250320501
2025-10-16

PALMITOYLATION OF THE ALTERNATIVE AMINO TERMINUS OF THE BTK-C ISOFORM CONTROLS SUBCELLULAR DISTRIBUTION AND SIGNALING

#120
20250320500
2025-10-16

NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE CONTAINING THE NUCLEIC ACID, PREPARATION METHOD THEREFOR, AND USE THEREOF

#121
20250319114
2025-10-16

NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION

#122
20250313878
2025-10-09

IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

#123
20250313845
2025-10-09

Compositions and Methods for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Editing

#124
20250313844
2025-10-09

INTERFERING RNA FOR INHIBITING PCSK9 GENE EXPRESSION AND USE THEREOF

#125
20250313843
2025-10-09

METHODS FOR TREATING HYPERCHOLESTEROLEMIA

#126
20250313842
2025-10-09

Compounds and Methods for Reducing LRRK2 Expression

#127
20250306008
2025-10-02

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MALIGNANT BREAST CANCER

#128
20250304969
2025-10-02

INHIBITORS OF EXPRESSION AND/OR FUNCTION

#129
20250304968
2025-10-02

UBE3A ANTISENSE THERAPEUTICS

#130
20250304967
2025-10-02

17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#131
20250304966
2025-10-02

TREATMENT OF CARDIOVASCULAR DISEASE

#132
20250304704
2025-10-02

HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR

#133
20250304532
2025-10-02

METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID

#134
20250302862
2025-10-02

SMALL RNA DRUG FOR INHIBITING ACTIVITY OF CANCER CELLS

#135
20250302861
2025-10-02

SMALL RNA AND USE THEREOF IN TREATMENT OF HYPERLIPIDEMIA

#136
20250297942
2025-09-25

OPTICAL TRANSMISSION SAMPLE HOLDER AND ANALYSIS, PARTICULARLY FOR HEMOGLOBIN

#137
20250297260
2025-09-25

COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSION

#138
20250297259
2025-09-25

ENGINEERED IMMUNE CELL WITH CIITA GENE KNOCK-OUT AND USE THEREOF

#139
20250297258
2025-09-25

OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF

#140
20250297024
2025-09-25

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

#141
20250295688
2025-09-25

COMPOSITIONS AND METHODS OF MODULATING XANTHINE DEHYDROGENASE

#142
20250283092
2025-09-11

MIRNA COMBINATION FOR THE PREVENTION AND TREATMENT OF CANCER

#143
20250283091
2025-09-11

METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA

#144
20250283090
2025-09-11

MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)

#145
20250283089
2025-09-11

TREATMENT OF A NON-ALCOHOLIC FATTY LIVER DISEASE

#146
20250283076
2025-09-11

TREATMENT OF CARDIOVASCULAR DISEASE

#147
20250282740
2025-09-11

COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO

#148
20250281642
2025-09-11

POLYNUCLEOTIDE FOR TREATMENT OF NEURODEGENERATIVE DISEASE, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, AND SCREENING METHOD

#149
20250281622
2025-09-11

FN3 DOMAIN-siRNA CONJUGATES AND USES THEREOF

#150
20250277220
2025-09-04

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#151
20250277219
2025-09-04

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#152
20250277218
2025-09-04

METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER

#153
20250277217
2025-09-04

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS ASSOCIATED WITH INFECTIOUS DISEASE

#154
20250276089
2025-09-04

CO-DELIVERY OF INHIBITORY NUCLEIC ACIDS AND GENOME EDITORS FOR TUMOR THERAPY

#155
20250270563
2025-08-28

TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT

#156
20250270562
2025-08-28

BIS-RNAI COMPOUNDS FOR CNS DELIVERY

#157
20250270561
2025-08-28

FUNCTIONAL NUCLEIC ACID MOLECULES

#158
20250269053
2025-08-28

LIPID NANOPARTICLES COMPRISING MANNOSE OR USES THEREOF

#159
20250263714
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#160
20250263713
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#161
20250263712
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#162
20250263711
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#163
20250263710
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#164
20250263709
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#165
20250263708
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#166
20250263707
2025-08-21

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#167
20250257358
2025-08-14

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#168
20250257357
2025-08-14

TREATMENT OF H3.3-MUTANT BRAIN CANCER WITH PNKP INHIBITORS

#169
20250255913
2025-08-14

NON-HALLUCINOGENIC PSYCHEDELIC FUNGI

#170
20250250575
2025-08-07

MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS

#171
20250250574
2025-08-07

SIRNA OR SALT THEREOF AND MEDICAMENT FOR INHIBITING EXPRESSION OF TMPRSS6 GENE, AND USE THEREOF

#172
20250250573
2025-08-07

POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

#173
20250250572
2025-08-07

XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#174
20250249118
2025-08-07

SARM1 RNAi AGENTS

#175
20250249117
2025-08-07

DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING MYOTONIC DYSTROPHY

#176
20250248379
2025-08-07

piRNA-BASED CONSTRUCTS FOR REGULATING GENE EXPRESSION AND METHODS OF USE THEREOF

#177
20250243501
2025-07-31

COMPOSITIONS AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS WITH DESIRABLE LEAF QUALITY VIA MANIPULATING LEAF QUALITY GENES

#178
20250243491
2025-07-31

PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOF

#179
20250243483
2025-07-31

Oligonucleotides

#180
20250242042
2025-07-31

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY

#181
20250235554
2025-07-24

METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY

#182
20250235470
2025-07-24

Methods and Compositions for Inhibiting the Growth and/or proliferation of MYC-Driven Tumor Cells

#183
20250230442
2025-07-17

RNA MOLECULES FOR TREATING FUNGI

#184
20250230441
2025-07-17

Nucleic acids for inhibiting expression of MASP-2 in a cell

#185
20250228886
2025-07-17

COMPOSITIONS AND METHODS FOR TREATMENT OF SEPSIS-RELATED DISORDERS

#186
20250228885
2025-07-17

COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH SIRNAS TARGETING GPAM

#187
20250228883
2025-07-17

Process to Inhibit or Eliminate Eosinophilic Diseases of the Airway and Related Conditions

#188
20250228875
2025-07-17

METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME

#189
20250223598
2025-07-10

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#190
20250223597
2025-07-10

LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CNS TISSUE

#191
20250223596
2025-07-10

ANTISENSE NUCLEIC ACID CAPABLE OF INHIBITING BIOSYNTHESIS OF CHONDROITIN SULFATE

#192
20250215435
2025-07-03

ANTI-HELICASE THERAPY FOR TREATMENT OF REPEAT EXPANSION DISEASE

#193
20250215434
2025-07-03

COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING DDX54 INHIBITOR AND CANCER IMMUNOTHERAPY AGENT

#194
20250215433
2025-07-03

RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use

#195
20250213698
2025-07-03

BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS

#196
20250213681
2025-07-03

NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION

#197
20250207139
2025-06-26

RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use

#198
20250207138
2025-06-26

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

#199
20250197866
2025-06-19

Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors

#200
20250197865
2025-06-19

PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF FIBROTIC DISEASE

#201
20250195554
2025-06-19

GENE EXPRESSION REGULATOR, AGENT FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE AND METHOD FOR IMPROVING DEMENTIA

#202
20250195514
2025-06-19

METHODS OF TREATING CHOLANGIOCARCINOMA

#203
20250194603
2025-06-19

COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY

#204
20250191692
2025-06-12

METHODS OF DESIGNING CONDITIONAL-ACTIVATABLE SMALL INTERFERING RNA SENSORS

#205
20250188475
2025-06-12

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#206
20250188474
2025-06-12

TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS

#207
20250188473
2025-06-12

Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors

#208
20250188472
2025-06-12

SARM1 RNA INTERFERENCE AGENTS

#209
20250188471
2025-06-12

NONCOVALENTLY BRANCHED OLIGONUCLEOTIDE COMPOSITIONS

#210
20250188470
2025-06-12

MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS

#211
20250186605
2025-06-12

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

#212
20250186439
2025-06-12

PYK2 INHIBITION MODULATES IMMUNE CELL FUNCTION

#213
20250179501
2025-06-05

METHODS OF TREATING CANCER AND/OR ENHANCING SENSITIVITY TO CANCER TREATMENT BY INCREASING TUMOR MUTATION BURDEN OR TUMOR INDELS

#214
20250179500
2025-06-05

PHARMACEUTICAL COMPOSITION COMPRISING SETMAR INHIBITOR FOR PREVENTING OR TREATING CANCER

#215
20250179499
2025-06-05

USE OF CDK16 AS TARGET IN PREPARATION OF MEDICINE FOR TREATING TRIPLE-NEGATIVE BREAST CANCER

#216
20250179498
2025-06-05

RNAI AGENT TARGETING MARC1 GENE, AND USE THEREOF

#217
20250171785
2025-05-29

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE

#218
20250171784
2025-05-29

APPLICATION OF MECHANICAL-FORCE SENSITIVE MACROPHAGE SUBSET IN PANCREATIC CANCER DIAGNOSIS OR PROGNOSIS EVALUATION

#219
20250171783
2025-05-29

ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE

#220
20250171779
2025-05-29

ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE

#221
20250170274
2025-05-29

GENE THERAPEUTICS FOR TREATING BONE DISORDERS

#222
20250170261
2025-05-29

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

#223
20250163429
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#224
20250163428
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#225
20250163427
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#226
20250163426
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#227
20250163425
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#228
20250163424
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#229
20250163423
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#230
20250163422
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#231
20250163421
2025-05-22

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

#232
20250160307
2025-05-22

BRAIN TUMOR MODEL

#233
20250154512
2025-05-15

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

#234
20250154511
2025-05-15

Products and Methods for Treatment of Amyotrophic Lateral Sclerosis

#235
20250146000
2025-05-08

COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)

#236
20250145999
2025-05-08

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PREKALLIKREIN (PKK) PROTEIN

#237
20250144152
2025-05-08

Transdifferentiation of Pancreatic Duct Cells Into Beta-Like Cells

#238
20250136994
2025-05-01

COMPOSITIONS AND METHODS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN HUMAN ANGELMAN SYNDROME

#239
20250136993
2025-05-01

TREATMENT FOR SOD1 ASSOCIATED DISEASE

#240
20250136992
2025-05-01

ANTI-PTEN RNA INTERFERENCE OLIGONUCLEOTIDES AND USES THEREOF

#241
20250136991
2025-05-01

METHOD OF MAKING BONE AND CARTILAGE

#242
20250136990
2025-05-01

ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE

#243
20250136936
2025-05-01

NUCLEIC ACID MODIFIED BIOLOGICAL CELL WITH EXPANSION-DEPENDENT GENE EXPRESSION

#244
20250129372
2025-04-24

Treatment Of Osteoarthritis With Procollagen Galactosyl Transferase 2 (COLGALT2) Inhibitors

#245
20250129371
2025-04-24

Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors

#246
20250129370
2025-04-24

METHOD FOR REDUCING HEPATIC TRIGLYCERIDES

#247
20250127890
2025-04-24

COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIOUS DISEASE-19 (COVID-19)

#248
20250122505
2025-04-17

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

#249
20250122504
2025-04-17

COMBINATIONS WITH MODULATORS OF PNPLA3 EXPRESSION

#250
20250121060
2025-04-17

IMMUNE CELLS WITH ENHANCED EFFICACY

#251
20250116656
2025-04-10

OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION

#252
20250115918
2025-04-10

Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors

#253
20250115917
2025-04-10

MODULATORY POLYNUCLEOTIDES

#254
20250115916
2025-04-10

MODULATION OF SUV39H1 EXPRESSION BY RNAS

#255
20250115915
2025-04-10

PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

#256
20250115907
2025-04-10

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA

#257
20250114368
2025-04-10

COMPOSITIONS AND METHODS RELATING TO PEDIATRIC NEUROMUSCULAR DISEASES AND NEUROGENERATIVE DISORDERS

#258
20250109164
2025-04-03

COMPOUNDS AND METHODS FOR THE MODULATION OF PROTEINS

#259
20250101432
2025-03-27

DEGRADATION OF RNA BY THE LYSOSOMAL PATHWAY

#260
20250101431
2025-03-27

ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA

#261
20250092404
2025-03-20

PIKFYVE ANTISENSE OLIGONUCLEOTIDES

#262
20250092403
2025-03-20

COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)

#263
20250084419
2025-03-13

Treatment Of Acne Rosacea With Pancreatic Lipase-Related Protein 3 (PNLIPRP3) Inhibitors

#264
20250084418
2025-03-13

COMPOSITIONS AND METHODS FOR SILENCING CARBONIC ANHYDRASE 2 EXPRESSION

#265
20250084417
2025-03-13

HEPARIN SULFATE BIOSYNTHESIS PATHWAY ENZYME IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#266
20250084416
2025-03-13

TARGETING OF XKR8 IN THERAPIES

#267
20250084415
2025-03-13

PHARMACEUTICAL COMPOSITION FOR SUPPRESSING INVASION OF CANCER, AND METHOD FOR SUPPRESSING INVASION OF CANCER

#268
20250084148
2025-03-13

COMPOSITIONS AND METHODS FOR TREATING CANCER

#269
20250082733
2025-03-13

m6A mRNA MODIFICATION IN CANCER TREATMENT

#270
20250073256
2025-03-06

PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

#271
20250066813
2025-02-27

MEANS AND METHOD FOR PREPARING VIRAL VECTORS AND USES OF SAME

#272
20250066794
2025-02-27

Application of PRDX5 and GPX4 Genes in Preparation of Drugs for Castration-resistant Prostate Cancer

#273
20250066793
2025-02-27

ANTI-SENSE OLIGONUCLEOTIDES AND USES THEREOF

#274
20250066792
2025-02-27

COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION

#275
20250066791
2025-02-27

RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

#276
20250064936
2025-02-27

COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION

#277
20250064808
2025-02-27

METHODS FOR THE TREATMENT OF NLRP3 RELATED DISORDERS

#278
20250059546
2025-02-20

ENHANCED PRODUCTION OF SQUALENE IN PLANT SYSTEMS

#279
20250057988
2025-02-20

Guide RNA That Targets A Mutant Human Guanylate Cyclase 2A Allele

#280
20250057973
2025-02-20

Exosomes for treating glioblastoma multiforme and manufacturing method thereof

#281
20250051782
2025-02-13

METHODS AND COMPOSITIONS RELATED TO RNA-TARGETED RHO SMALL GTPase RND3/RhoE THERAPY

#282
20250051781
2025-02-13

COMPOUNDS AND METHODS FOR MODULATING GLYCOGEN SYNTHASE 1

#283
20250051780
2025-02-13

COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING

#284
20250049804
2025-02-13

FERROCHELATASE INHIBITORS AND METHODS OF USE

#285
20250043289
2025-02-06

3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#286
20250034577
2025-01-30

RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use

#287
20250034576
2025-01-30

Double Stranded Oligonucleotide For Modulating JAK1 Expression

#288
20250034575
2025-01-30

OLIGONUCLEOTIDES FOR DGAT2, FASN, OPN, AND NOX4 MODULATIONS

#289
20250034574
2025-01-30

METHODS OF SILENCING EXPRESSION OF GENES AND USES THEREOF

#290
20250034566
2025-01-30

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

#291
20250032644
2025-01-30

COMPOSITIONS AND METHODS FOR TREATING FAN1 ASSOCIATED TRINUCLEOTIDE REPEAT EXPANSION DISORDERS

#292
20250027088
2025-01-23

Compositions and Methods of Generating Novel amiRNA

#293
20250027087
2025-01-23

MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE

#294
20250027079
2025-01-23

USE OF FANA ANTISENSE OLIGONUCLEOTIDES FOR THE PREVENTION AND MANAGEMENT OF HUANGLONGBING AND ZEBRA CHIP DISEASES

#295
20250025488
2025-01-23

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS

#296
20250025478
2025-01-23

METHODS OF TARGETING RNF213 SIGNALING PATHWAY FOR TREATING DISEASES

#297
20250019709
2025-01-16

NOVEL OXO-RNA COMPOSITIONS AND THE RELATED APPLICATIONS THEREOF

#298
20250019708
2025-01-16

METHODS FOR THE TREATMENT OF HRD CANCER AND BRCA-ASSOCIATED CANCER

#299
20250011815
2025-01-09

AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS

#300
20250011802
2025-01-09

Methods for the Modification of Cells, Modified Cells and Uses Thereof